• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Combined Use of ^Sup 99m^Tc-Sestamibi and ^Sup 99m^Tc-V-DMSA in the Assessment of Chemotherapy Effectiveness in Patients With Multiple Myeloma

Posted on: Wednesday, 15 June 2005, 03:00 CDT

This study determined the role of the combined use of ^sup 99m^Tc- sestamibi and ^sup 99m^Tc-pentavalent dimercaptosuccinic acid (V- DMSA) scintigraphy in evaluating the effectiveness of chemotherapy in patients with multiple myeloma. Methods: In 20 patients with multiple myeloma who had received or were receiving chemotherapy, ^sup 99m^Tc-sestamibi and ^sup 99m^Tc-V-DMSA scanning was performed to evaluate the effectiveness of chemotherapy. Results: In group A (11 patients with active disease), 42 ^sup 99m^Tc-sestamibi- positive lesions were found. Thirty-seven of those lesions were also positive for ^sup 99m^Tc-V-DMSA uptake, as were 16 additional lesions (nonactive) (NAL). Thus, in group A, the total number of positive lesions (TPL) detected was 58 and the NAL/TPL ratio was 16:58. In group B (9 patients in remission), 5 ^sup 99m^Tc- sestamibi-positive lesions were found. A further 22 lesions were also positive for ^sup 99m^Tc-V-DMSA uptake. Thus, in group B, the NAL/TPL ratio was 22:27. Therefore, the NAUTPL ratios considered to represent effectively treated lesions were 27.6% and 81.5% for groups A and B, respectively. Conclusion: Combined use of the 2 agents allows the effectiveness of chemotherapy to be evaluated through a comparison of NAL and TPL multiple myeloma lesions even in the absence of a baseline study.

Key Words: ^sup 99m^Tc-MIBI; ^sup 99m^Tc-V-DMSA; multiple myeloma; chemotherapy; treatment

J Nucl Med 2005; 46:978-982

Multiple myeloma (MM) is a neoplastic disease characterized by the proliferation of monoclonal myeloma cells that seed throughout the bone marrow. Standard diagnostic imaging methods, such as skeletal radiography and bone scanning, have certain limitations for detecting the presence and extent of bone disease for staging and particularly for following up patients with MM.

The usefulness of follow-up ^sup 99m^Tc-sestamibi (MIBI) scanning in detecting active disease in patients with MM is well established. Uptake of ^sup 99m^Tc-MIBI has been reported as correlating well with the degree of bone marrow MM involvement, in particular when used in the follow-up of treated patients with already documented bone lesions (1-4). However, if baseline data are not available it is not possible to estimate the chemotherapy effect using a single ^sup 99m^Tc-MIBI examination.

^sup 99m^Tc-Pentavalent dimercaptosuccinic acid (V-DMSA) has been shown to concentrate in some tumors (5,6), including MM (7,8), as well as in inflammatory conditions such as osteomyelitis (5), psoas muscle abscess (9), bone and joint infection (10), intestinal inflammation (11), and active inflammatory bowel disease (12) in which several cell types, such as macrophages, histiocytes, and fibroblasts, are present.

Effective chemotherapy dramatically reduces viable MM cells because of apoptosis. We hypothesize that unlike ^sup 99m^Tc-MIBI, ^sup 99m^Tc-V-DMSA will continue to concentrate in MM lesions after chemotherapy because of factors other than viable MM cells such as macrophages. Thus, we believe that a relatively increased ^sup 99m^Tc-V-DMSA uptake, compared with ^sup 99m^Tc-MIBI uptake, should be a good index of chemotherapy effectiveness.

The aim of the study was to determine the role of the combined use of ^sup 99m^Tc-MIBI and ^sup 99m^Tc-V-DMSA scintigraphy in the evaluation of chemotherapy effectiveness in patients with MM.

MATERIALS AND METHODS

Patients

Twenty MM patients (11 women and 9 men) with a mean age of 63 y (range, 26-87 y) were included in the study. All patients had received or were receiving chemotherapy. The onset of the disease ranged from 1 to 70 mo (mean SD, 25 23 mo) before the study. The criteria of Salmon and Durie were used for initial staging of tumor burden, and the staging system of Bataille was used for disease activity. Eleven patients (group A) had clinically active disease, and 9 patients (group B) had disease that was in complete or partial remission (at least a 50% decrease in M protein in serum or urine).

Fifteen patients were receiving chemotherapy: 11 of 11 from group A and 4 of 9 from group B. The remaining 5 of 9 patients from group B had undergone chemotherapy between 5 mo and 2.5 y before the study. The conventional chemotherapy that was administered was vincristine, doxorubicin, and dexamethasone or pegylated doxorubicin, vincristine, and reduced-schedule dexamethasone. Various combination therapies were also used as salvage therapies. Thalidomide, an oral agent, was also often used as salvage therapy for myeloma patients, alone or in combination with dexamethasone or melphalan and dexamethasone. One to 6 therapies (2.8 1.9) were administered to group A patients and 1-3 therapies (1.9 0.8) to group B patients (P = not statistically significant [NS]). The duration of remission in group B was 1-30 mo.

Imaging

The ^sup 99m^Tc-MIBI (Carcliolite; Bristol Myers Squibb GmbH) was prepared according to the manufacturer's instructions. Each patient received 666 MBq of ^sup 99m^Tc MIBI intravenously, and the scans were obtained 10 min after injection. ^sup 99m^Tc-V-DMSA was prepared using a commercially available kit (DMS(V)/Demoscan; National Center of Physical Sciences, Institute of Radioisotopes and Radiodiagnostics "Democritus"), 740 MBq were injected intravenously, and 2 h later the scintigrams were obtained. The studies were performed at intervals of at least 48 h to avoid carryover of image data and, for patients who were receiving chemotherapy, were performed in the middle of a chemotherapy cycle (ninth-12th posttherapy days). All scintigrams were obtained on a single-head tomographic -γ-camera (Sophycamera DS7; Sopha Medical Vision International) coupled to a dedicated NXT computer system (Sophy NxT; Sopha Medical Vision International). Spot images of the whole body were obtained with a low-energy all-purpose collimator using a 20% window centered at 140 keV.

Two experienced nuclear medicine physicians unaware of the patient's disease status, disease stage, and other clinical data reported scintigraphic findings. The ^sup 99m^Tc-MIBI findings were classified as pattern N when only normal physiologic uptake was present, pattern D when diffuse bone marrow uptake was present, pattern F when areas of focal uptake were present, or pattern F + D when both patterns were present. The presence of focal increased ^sup 99m^Tc-V-DMSA activity was characterized as a positive finding. Disagreement was resolved by consensus or by obtaining a third opinion.

TABLE 1

Group A: Patient Data and Scintigraphic Results

Statistical Analysis

The 2-tailed Mann-Whitney nonparametric test was used to evaluate differences. P values < 0.05 were considered statistically significant.

RESULTS

An overview of the patients, their disease, and scintigraphic data are summarized in Tables 1 and 2.

There was no statistically significant difference either in the time from onset of the disease in the 2 groups, which ranged from 1 to 60 mo before the study (27 25 mo) in group A and from 5 to 70 mo (23 21 mo) in group B, or in the number of therapies they had received. No correlation was found in efficacy among different chemotherapy regimens.

Of the 11 patients from group A, 4 patients showed a diffuse pattern of ^sup 99m^Tc-MIBI uptake (Fig. 1). Focal areas of ^sup 99m^Tc-MIBI uptake were the only pathologic finding in 4 patients and were combined with a diffuse pattern of bone marrow uptake in 3 patients. ^sup 99m^Tc-V-DMSA findings were focally positive in 8 patients, and 3 patients had normal ^sup 99m^Tc-V-DMSA findings.

In group B, 6 patients had normal ^sup 99m^Tc-MIBI findings and 3 patients showed focal areas of uptake. ^sup 99m^Tc-V-DMSA findings were focally positive in 8 patients.

The total number of ^sup 99m^Tc-MIBI-positive or ^sup 99m^Tc-V- DMSA-positive lesions (TPL) was determined. Lesions that were ^sup 99m^Tc-V-DMSA-positive but ^sup 99m^Tc-MIBI-negative were considered to be nonactive lesions (NAL). The NAL/TPL ratio was calculated for both groups.

TABLE 2

Group B: Patient Data and Scintigraphic Results

In group A, 42 ^sup 99m^Tc-MIBI-positive lesions were found. Thirty-seven of those lesions were also positive for ^sup 99m^Tc-V- DMSA uptake, as were 16 additional lesions that did not accumulate ^sup 99m^Tc-MIBI (Fig. 2). Thus, a total of 58 MM lesions were detected. In group B, 5 ^sup 99m^Tc-MIBI-positive lesions were found, all of which were also positive for ^sup 99m^Tc-V-DMSA uptake, as were 22 additional lesions that did not accumulate ^sup 99m^Tc-MIBI (Figs. 3 and 4). Thus, a total of 27 MM lesions were detected.

The overall NAL/TPL ratio in group A was 16:58, which means that 27.6% of the lesions were considered as having been effectively treated. In group B, the NAL/TPL ratio was 22:27, which means that 81.5% of the lesions were considered as having been effectively treated (P < 0.001) (Fig. 5). The individual NAL/TPL ratios ranged from 0 to 0.75 (mean, 0.17) for patients in group A and from 0.50 to 1 (mean, 0.88) for patients in group B (P < 0.001) (Fig. 6).

FIGURE 1. Patient 3 from group A, with diffuse pattern of ^sup 99m^Tc-MIBI findings (A) and negative ^sup 99m^Tc-V-DMSA findings (B). At top is posterior view of pelvis; at bottom is anterior view of thora\x. NAL/TPL ratio = 0.

FIGURE 2. Patient 7 from group A, with 16 ^sup 99m^Tc-MIBI- positive lesions (A) and 15 ^sup 99m^Tc-V-DMSA-positive lesions (B). At top is posterior view of head, neck, and upper thorax; at bottom is anterior view of thighs. NAL/TPL ratio = 5/21 = 0.24.

A negative correlation was observed between NAL/TPL ratio and the number of therapies in all patients (r = -0.27; P = NS). A correlation between NAL/TPL ratio and the number of therapies was observed in group A patients (r = -0.015; P = NS). In group B, the NAL/TPL ratio was inversely correlated with the duration of remission (r = -0.19) and the number of therapies (r = - 0.06), but not significantly so.

FIGURE 3. Patient 2 from group B, with normal pattern of ^sup 99m^Tc-MIBI findings (A) and 2 ^sup 99m^Tc-V-DMSA-positive lesions (arrows) in lower right ribs (B). Images are posterior view of thorax and upper lumbar region. NAL/TPL ratio = 2/2 = 1.

The disease status for the studied patients 2 y after the scintigraphies was as follows: From group A, 4 patients were stable (with active disease), 1 patient was in remission, and 6 patients had died. The mean NAL/TPL ratio for the 6 patients who died was 0.087. In group B, 8 patients were still in remission and 1 patient had died.

DISCUSSION

^sup 99m^Tc-MIBI, a myocardial perfusion agent, has been proposed as a tracer for several neoplasias, including multiple myeloma (1- 4). ^sup 99m^Tc-MIBI is thought to be taken up by malignant tissues through accumulation in the mitochondria of viable tumor cells. In addition, retention of ^sup 99m^Tc-MIBI in tumor cells may be governed by the multidrug resistance 1 system. Therefore, the sensitivity of ^sup 99m^Tc-MIBI scanning is considerably affected by many conditions, such as multidrug resistance and chemotherapy (2,13).

^sup 99m^Tc-V-DMSA is a well-known tumor-seeking agent that accumulates in primary tumors and in metastatic lesions. Its accumulation is independent of multidrug resistance (14). The ability of ^sup 99m^Tc-V-DMSA to accumulate in tumor cells is thought to depend, in part, on the acidification of the tumor cell environment (75). The high glycolysis rate found in aggressive or malignant tumors results in increased production of lactic acid, which is thought to be a cause of acidic pH in tumors. Acidification induced by glucose administration results in increased ^sup 99m^Tc- V-DMSA accumulation in tumors (16). White cells and fibroblasts also use glucose as an energy source during their high metabolic activity and proliferation, allowing imaging of infections and inflammation by ^sup 18^F-FDG PET (17,18). This may explain the accumulation of ^sup 99m^Tc-V-DMSA in inflammatory processes.

FIGURE 4. Patient 7 from group B, with normal pattern of ^sup 99m^Tc-MIBI findings (A) and 2 ^sup 99m^Tc-V-DMSA-positive lesions (arrows) in vertebra bodies (B). Images are posterior view of thoracic and lumbar region. NAL/TPL ratio = 2/2 = 1.

FIGURE 5. NAL and ^sup 99m^Tc-MIBI or ^sup 99m^Tc-V-DMSA TPL detected in all patients in the 2 groups.

In a previous study, ^sup 99m^Tc-MIBI was compared with ^sup 18^F- FDG PET in a patient with diffuse MM during preparation for bone marrow transplantation (19). ^sup 99m^Tc-MIBI appeared to indicate the extent of the disease, whereas ^sup 18^F-FDG PET showed activity in only some of the areas that demonstrated ^sup 99m^Tc-MIBI uptake. These areas demonstrated active disease progression associated with pain. The authors inferred that inflammatory activity associated with tumor proliferation might be an additional factor leading to increased ^sup 18^F-FDG uptake. No areas of exclusively ^sup 18^F- FDG uptake were found, although no imaging took place after high- dose chemotherapy.

FIGURE 6. Distribution of individual NAL/TPL ratios for the 2 groups.

^sup 99m^Tc-V-DMSA accumulation in infection and inflammation has been well documented. Lee et al. (70) found that ^sup 99m^Tc-V-DMSA showed greater sensitivity and accuracy than did ^sup 67^Ga in the assessment of bone and joint infection, although the difference was not statistically significant. Koutroubakis et al. (72) reported that ^sup 99m^Tc-V-DMSA scintigraphy had 92% sensitivity and 86% specificity in the detection of active inflammatory bowel disease. Those authors also found a significant correlation between disease activity indices and scintigraphy score.

In a report of ours, an important role for inflammation or fibrosis in ^sup 99m^Tc-V-DMSA uptake by tumors was proposed (8). We compared the ^sup 99m^Tc-MIBI and ^sup 99m^Tc-V-DMSA uptake changes in MM focal lesions in response to high-dose chemotherapy. The high- dose chemotherapy eliminated all ^sup 99m^Tc-MIBI uptake by the lesions, whereas ^sup 99m^Tc-V-DMSA uptake was increased in lesions presenting significant initial ^sup 99m^Tc-MIBI uptake. In 1 lesion that demonstrated this phenomenon, MRI showed necrosis of the MM tumor. This reversed result after chemotherapy implies that ^sup 99m^Tc-V-DMSA accumulation in MM lesions does not necessarily reflect viable tumor tissue.

In our study, we found that patients with active disease had a significantly lower ratio of ^sup 99m^Tc-V-DMSA-positive but ^sup 99m^Tc-MIBI-negative lesions to total scintigraphically demonstrable MM lesions (NAL/TPL ratio) than did patients in remission, in whom ^sup 99m^Tc-V-DMSA-positive lesions were much more numerous than ^sup 99m^Tc-MIBI-positive lesions.

Prognosis in MM depends on the extent of disease and the appropriate therapy. From the standpoint of disease extension alone, ^sup 99m^Tc-MIBI scintigraphy distinguished group A from group B since no patient from group A had normal ^sup 99m^Tc-MIBI findings whereas 6 of 9 patients from group B had normal ^sup 99m^Tc-MIBI findings. The ^sup 99m^Tc-MIBI-positive lesions numbered 42 and 5 in groups A and B, respectively. The NAL/TPL ratio appears to be a separate parameter in the determination of therapeutic effectiveness. The NAL/TPL ratio of group A was significantly lower than that of group B (0.276 vs. 0.815). In addition, those group A patients who died within 2 y of the scintigraphic studies had a mean NAL/TPL ratio of 0.087-even lower than for the group as a whole (mean NAL/TPL ratio, 0.17)-which strengths the value of this ratio.

No significant correlation was found between the NAL/ TPL ratio and either the number of pretherapies for all patients or the duration of remission for group B patients. Also, no correlation was found in efficacy among different chemotherapy regimens. But since the number of our patients is still limited, we believe that we need more studies with larger numbers of patients to reach more accurate conclusions about these parameters and to determine any threshold for the NAL/TPL ratio.

CONCLUSION

Our results indicate that combined use of ^sup 99m^Tc-MIBI and ^sup 99m^Tc-V-DMSA scanning during chemotherapy allows evaluation of the effectiveness of the administered chemotherapy. Also, the large percentage of NAL in patients in remission supports the hypothesis that ^sup 99m^Tc-V-DMSA is not only a tumor-dependant analog. We believe that we need more studies with a greater number of patients to prove this hypothesis and to determine the ratio threshold above which the patients' therapy can be considered effective.

REFERENCES

1. Pace L. Catalane L. Del Vecchio S. et al. Predictive value of technetiuin-99m sestamibi in patients with multiple myeloma and potential role in (he follow-up. Ear J Nucl Med. 2001;28:304-312.

2. Balleari E, Villa G, Garre S, et al. Technetium-99m-sestamibi scintigruphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease. Haeniatologicn. 2001;86:78-84.

3. Pace L, Catalano L. Pinto A, et al. Different patterns of technetium-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med. 1998;25:714-720.

4. Tirovola EB, Biassoni L, Britton KE, Kaleva N, Kouykin V, Malpas JS. The use of ^sup 99m^Tc-MIBI scanning in multiplemyeloma.Br J Cancer. 1996:74:1815-1820.

5. Ohta H. Endo K. Fujita T, et al. Clinical evaluation of tumour imaging using 99Tc(V)m dimercaptosuccinic acid, a new tumour- seeking agent. Nucl Med Commun. 1988:9:105-116.

6. Papantoniou V, Christodoulidou J. Papadaki E, et al. ^sup 99m^Tc-(V) DMSA scintimammography in the assessment of breast lesions: comparative study with ^sup 99m^Tc-MIBI. Ear J Nucl Med. 2001:28:923-928.

7. Ohnishi T, Noguchi S, Murakami N, et al. Pentavalent technetium-99m-DMSA uptake in a patient having multiple myeloma without amyloidosis. J Nucl Med. 1991:32:1785-1787.

8. Athanasoulis T, Koutsikos J, Moulopoulos LA, Tsiouris S. Dimopoulos MA, Zerva C. Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy. CHn Nucl Med. 2003:28:631-635.

9. Lee BF, Chen CJ, Yang CC, Yu HS. Psoas muscle abscess causing fever of unknown origin: the value of Tc-99m (V) DMS imaging. Clin Nucl Med. 1997;22:789-790.

10. Lee BF, Chiu NT, Chang JK, Liu GC, Yu HS. Technetium-99m(V)- DMSA and gallium-67 in the assessment of bone and joint infection. J Nucl Med. 1998:39: 2128-2131.

11. Lee BF. Chiu NT. Wu DC. et al. Use of ^sup 99m^Tc (V)DMSA scinligraphy in the detection and localization of intestinal inflammation: comparison of findings and colonoscopy and biopsy. Radiology. 2001:220:381-385.

12. Koutroubakis IE, Koukouraki SI, Dimoulios PD, Velidaki AA. Karkavitsas NS, Kouroumalis EA. Active inflammatory bowel disease: evaluation with ^sup 99m^Tc (V) DMSA scintigraphy. Radiology. 2003:229:70-74.

13. Catalano L, Pace L. Califano C, et al. Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy. Haematologica. 1999:84:119-124.

14. Denoyer D, Perek N. Le Jeune N, Frere D, Dubois F. The multidrug resistance of in vitro tumor cell lines derived from human breast carcinoma MCF-7 does not influence pentavalent technetium- 99m-dimereaptosuccinicaeid uptake. Cancer Biother Radiopharm. 2003:18:791-801.

15. Horiuchi K, SaJi H, Yokoyama A. pH sensitive properties of Tc(V)-DMS: analytical and in vitro cellular studies. Nucl Med BwI 1998:25:689-695.

16. Horiuchi K. Saji H, Yokoyama A. Tc(V)-DMS tumor localization mechanism: a pH-sensitive Tc(V)-DMS-cnhanced target/nontarget ratio by glucose-mediated acidosis. Nucl Med Dial. 1998:25:549-555.

17. Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG-PET. Eur J Nucl Med. 2000:27:822-832.

18. Drieskens O, Blockmans D, Van den Bruel A, Mortelmans L. Riedel's thyroiditis and retroperitoneal fibrosis in multifocal fibrosclerosis: positron emission tomographic findings. CHn Nucl Med. 2002:27:413-415.

19. El-Shirbiny AM, Yeung H, Imbriaco M, Michaeli J, Macapinlac H, Larson SM. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med. 1997:38:1208-1210.

John Koutsikos, MD1; Theodoros Athanasoulis, MD1; Athanasios Anagnostopoulos, MD2; Antigone Velidaki, MD3; Marianthi Passadi1; Meletios Athanasios Dimopoulos, MD, PhD2; and Cherry Zerva, MD, PhD1

1 Department of Nuclear Medicine, "Alexandra" University Hospital, Athens, Greece; 2 Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; and 3 Department of Nuclear Medicine, Livadia Medical Center, Livadia, Greece

Received Jul. 12, 2004; revision accepted Jan. 23, 2005.

For correspondence or reprints contact: John Koutsikos, MD, 44- 48 Martinegou St., N. Filothei, 11524, Athens, Greece.

E-mail: jtkoutsik@yahoo.gr

Copyright Society of Nuclear Medicine Jun 2005

Source: Journal of Nuclear Medicine, The

More News in this Category